Although immunological approaches seem to be efficient, several studies demonstrated that CTCs of carcinoma origin have a heterogeneous expression of EpCAM and/or CK markers especially when they are in epithelial to mesenchymal transition (EMT) status. This evidence concerns the gene EPCAM and carcinoma.